文献速递泌尿生殖介入MR

3-T磁共振引导下经直肠靶向前列腺活检:基于前列腺影像报告和数据系统第2版的诊断效能

In-Bore 3-T MR-guided Transrectal Targeted Prostate Biopsy: Prostate Imaging Reporting and Data System Version 2-based Diagnostic Performance for Detection of Prostate Cancer.
PubMed 文献 · Radiology · 2016-11-18

本研究在106例男性134个靶点中行3-T磁共振引导下经直肠靶向前列腺活检,前列腺癌检出率为59.4%(63/106例)和53.7%(72/134个靶点),其中68.0%(49/72)为临床显著癌(Gleason评分≥7)。PI-RADS第2版2、3、4、5类靶点的阳性检出率分别为13.0%、19.4%、78.0%、82.8%,PI-RADS第2版与第1版的曲线下面积无差异。

要点

  • PI-RADS第2版4类和5类靶点阳性率分别为78.0%和82.8%,2类和3类分别为13.0%和19.4%。
  • 阳性靶点患者的前列腺体积更小(47.2 cm3 vs 75.4 cm3)、PSA密度更高(0.16 vs 0.10)。
  • PI-RADS第2版与第1版的曲线下面积无差异,并发症为尿脓毒症1例(0.9%)。

核心结论

  • 在按PI-RADS第1版和第2版分层时,3-T磁共振引导下经直肠靶向前列腺活检对前列腺癌诊断安全且有效。

研究设计与样本

  • 本研究为经机构审查委员会批准、符合HIPAA的研究,在106例男性134个靶点中行3-T磁共振引导下经直肠靶向前列腺活检。
  • 纳入人群包括未行前列腺活检者、既往活检阴性且PSA升高者、或既往前列腺癌史且PSA升高者。
  • 采用临床诊断性3-T磁共振成像结合磁共振引导下前列腺活检,并收集病理数据。
  • 按患者和靶点分析磁共振引导下活检的诊断检出率,比较活检靶点阴性者与阳性者之间的差异。
  • 比较PI-RADS第1版与第2版的逻辑回归结果和曲线下面积。

关键影像表现/征象

  • 阳性靶点患者的表观扩散系数值低于阴性靶点患者(875 × 10-6 mm2/sec vs 1111 × 10-6 mm2/sec,P < .01)。
  • 阳性靶点患者的前列腺体积小于阴性靶点患者(47.2 cm3 vs 75.4 cm3,P < .01)。
  • 阳性靶点患者的PSA密度高于阴性靶点患者(0.16 vs 0.10,P < .01)。
  • 阳性靶点患者中PI-RADS第2版3-5类评分比例高于阴性靶点患者。

诊断标准与关键数值

  • 106例患者中63例(59.4%)检出前列腺癌,134个靶点中72个(53.7%)检出前列腺癌。
  • 72个阳性靶点中49个(68.0%)为临床显著癌(Gleason评分≥7)。
  • PI-RADS第2版2类靶点阳性检出率为3/23(13.0%)。
  • PI-RADS第2版3类靶点阳性检出率为6/31(19.4%)。
  • PI-RADS第2版4类靶点阳性检出率为39/50(78.0%),5类靶点阳性检出率为24/29(82.8%)。

临床应用与阅片要点

  • 阅片和报告时可参考PI-RADS第2版分类:4类和5类靶点阳性率较高(78.0%和82.8%),2类和3类靶点阳性率较低(13.0%和19.4%)。
  • 阳性靶点患者更常见较低的表观扩散系数值、较小的前列腺体积和较高的PSA密度。
  • 本研究报道1例并发症(尿脓毒症,0.9%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To determine the diagnostic yield of in-bore 3-T magnetic resonance (MR) imaging-guided prostate biopsy and stratify performance according to Prostate Imaging Reporting and Data System (PI-RADS) versions 1 and 2. Materials and Methods This study was HIPAA compliant and institution review board approved. In-bore 3-T MR-guided prostate biopsy was performed in 134 targets in 106 men who (a) had not previously undergone prostate biopsy, (b) had prior negative biopsy findings with increased prostate-specific antigen (PSA) level, or (c) had a prior history of prostate cancer with increasing PSA level. Clinical, diagnostic 3-T MR imaging was performed with in-bore guided prostate biopsy, and pathology data were collected. The diagnostic yields of MR-guided biopsy per patient and target were analyzed, and differences between biopsy targets with negative and positive findings were determined. Results of logistic regression and areas under the curve were compared between PI-RADS versions 1 and 2. Results Prostate cancer was detected in 63 of 106 patients (59.4%) and in 72 of 134 targets (53.7%) with 3-T MR imaging. Forty-nine of 72 targets (68.0%) had clinically significant cancer (Gleason score ≥ 7). One complication occurred (urosepsis, 0.9%). Patients who had positive target findings had lower apparent diffusion coefficient values (875 × 10-6 mm2/sec vs 1111 × 10-6 mm2/sec, respectively; P < .01), smaller prostate volume (47.2 cm3 vs 75.4 cm3, respectively; P < .01), higher PSA density (0.16 vs 0.10, respectively; P < .01), and higher proportion of PI-RADS version 2 category 3-5 scores when compared with patients with negative target findings. MR targets with PI-RADS version 2 category 2, 3, 4, and 5 scores had a positive diagnostic yield of three of 23 (13.0%), six of 31 (19.4%), 39 of 50 (78.0%), and 24 of 29 (82.8%) targets, respectively. No differences were detected in areas under the curve for PI-RADS version 2 versus 1. Conclusion In-bore 3-T MR-guided biopsy is safe and effective for prostate cancer diagnosis when stratified according to PI-RADS versions 1 and 2. ©RSNA, 2016.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Tan N, Lin WC, Khoshnoodi P, et al. In-Bore 3-T MR-guided Transrectal Targeted Prostate Biopsy: Prostate Imaging Reporting and Data System Version 2-based Diagnostic Performance for Detection of Prostate Cancer. Radiology. 2016. PMID: 27861110. doi:10.1148/radiol.2016152827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。